Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant in recent onset chronic cough
NCT04193202Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of gefapixant in refractory chronic cough (RCC), unexplained chronic cough, sponsored by Merck & Co.. Started May 2020; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT04193202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193202.